TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25238031

Group type: EXPERIMENTAL
Intervention: Full-arch implant-fixed prostheses (G1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Multiple implant splinting via acrylic resin denture bases (G2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 29
Study: 24060817

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/mL
Number of subjects: 299
Study: 22944060

Group type: EXPERIMENTAL
Intervention: Domestic rosuvastatin, 10 mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: CRESTOR, 10 mg/day
Number of subjects: 83
Study: 20710084

Group type: EXPERIMENTAL
Intervention: Augmented low Dye (ALD) taping
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 13

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 13
Study: 17411468

Group type: EXPERIMENTAL
Intervention: Comprehensive physical activity promotion programme
Number of subjects: 764

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 764
Study: 15868634

Group type: EXPERIMENTAL
Intervention: Custom-made semirigid foot orthotics with shock absorbing posts (n = 15)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Off-the-shelf flat neoprene shoe inserts (n = 12)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive athletic shoes with medial longitudinal arch support and shock absorbing soles (n = 13)
Number of subjects: 40
Study: 11915378

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 12.5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 25 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study: 9793701

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan for treating migraine attacks
Number of subjects: 91
Study: 7795344

Group type: EXPERIMENTAL
Intervention: Intervention campaign to discourage prone sleeping
Number of subjects: 94
Study: 1977980

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (metronidazole 20 mg/kg or 5 mg/kg daily, amoxycillin 25 mg/kg daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 28976

Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.5 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both doses (1.0 mg and 1.5 mg)
Number of subjects: 28
Study: 31788995

Group type: EXPERIMENTAL
Intervention: 4-weekly carboplatin area under the curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Number of subjects: 45

Group type: COMPARATOR
Intervention: Observation, n=21
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4-weekly carboplatin area under curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Number of subjects: 45
Study: 30531572

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 56
Study: 28416342

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 1184
Study: 26248312

Group type: EXPERIMENTAL
Intervention: Blocked schedule, extraneous focus condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraneous attention
Number of subjects: 0
Study: 23141780

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 22043465

Group type: EXPERIMENTAL
Intervention: All-on-2 group
Number of subjects: 60

Group type: COMPARATOR
Intervention: All-on-4 group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 18592418

Group type: EXPERIMENTAL
Intervention: cNIRS monitoring
Number of subjects: 26

Group type: COMPARATOR
Intervention: Serum from children undergoing evaluation for fever in the Emergency department (control)
Number of subjects: 26
Study: 16363021

Group type: EXPERIMENTAL
Intervention: Early bilateral breast reduction surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (delayed surgery)
Number of subjects: 73
Study: 12745614

Group type: EXPERIMENTAL
Intervention: Intrathecal BDNF therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10784225

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 93

Group type: COMPARATOR
Intervention: Human soluble insulin (Humulin S)
Number of subjects: 93
Study: 8818605

Group type: EXPERIMENTAL
Intervention: Total Design Method (TDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual procedure
Number of subjects: 0
Study: 1329477

Group type: EXPERIMENTAL
Intervention: Once-daily lisinopril (5-20 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Twice-daily captopril (12.5-50 mg)
Number of subjects: 31
Study: 4067891

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (non-exercised)
Number of subjects: 305
Study: 30567400

Group type: EXPERIMENTAL
Intervention: IQOSTM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cigarette
Number of subjects: 30
Study: 28042578

Group type: EXPERIMENTAL
Intervention: Aromatherapy (inhalation of a blend of 1.0 mL of lemon and 0.5 mL of ginger essential oils)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (inhalation of distilled water as placebo)
Number of subjects: 71
Study: 24296904

Group type: COMPARATOR
Intervention: Paraprofessional home visits
Number of subjects: 735

Group type: COMPARATOR
Intervention: Nurse home visits
Number of subjects: 735
Study: 22274951

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenously on days 1 and 4 (schedule 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenously on days 1, 3, and 5 (schedule 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both dosing schedules of palonosetron
Number of subjects: 30
Study: 20637970

Group type: EXPERIMENTAL
Intervention: Avanafil 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Avanafil (all doses)
Number of subjects: 30
Study: 19099009

Group type: EXPERIMENTAL
Intervention: GW406381 50 mg
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 1980

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1980

Group type: EXPERIMENTAL
Intervention: GW406381 (1, 5, 10, 25, or 50 mg)
Number of subjects: 1980
Study: 15914988

Group type: COMPARATOR
Intervention: 0 applications of plantibody
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2 applications of plantibody
Number of subjects: 56

Group type: COMPARATOR
Intervention: 4 applications of plantibody
Number of subjects: 56

Group type: COMPARATOR
Intervention: 6 applications of plantibody
Number of subjects: 56
Study: 16400293

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer drugs (lamotrigine, levetiracetam, topiramate, zonisamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug combinations, vagal nerve stimulation, felbamate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study: 11746069

Group type: EXPERIMENTAL
Intervention: Communication group (taught pain management and communication skills)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (taught to use pain-intensity scales)
Number of subjects: 31
Study: 9430449

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 0.17 U/kg i.m.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Human corticotropin-releasing hormone (hCRH) 2.0 microg/kg i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) and AVP co-administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) and hCRH co-administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CRH and AVP co-administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) alone
Number of subjects: 7
Study: 8495455

Group type: EXPERIMENTAL
Intervention: Propranolol LA 80 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propranolol LA 160 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3003166

Group type: EXPERIMENTAL
Intervention: Water Pik oral irrigator
Number of subjects: 0
Study: 31666688

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nitrogen (placebo)
Number of subjects: 28
Study: 30354399

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 228

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 228
Study: 27240799

Group type: EXPERIMENTAL
Intervention: CHG-impregnated PICC line
Number of subjects: 167

Group type: COMPARATOR
Intervention: non-CHG PICC line
Number of subjects: 167
Study: 25218827

Group type: COMPARATOR
Intervention: Gabapentin 1800 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg + Donepezil 5 mg
Number of subjects: 30
Study: 22931620

Group type: EXPERIMENTAL
Intervention: Oral intestinal probiotics (Jinshuangqi Tablets, 2.0 g, 3 times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral intestinal antimicrobial agents
Number of subjects: 60
Study: 21095487

Group type: EXPERIMENTAL
Intervention: Norditropin FlexPro
Number of subjects: 56

Group type: COMPARATOR
Intervention: easypod
Number of subjects: 56

Group type: COMPARATOR
Intervention: Genotropin
Number of subjects: 56
Study: 18388222

Group type: EXPERIMENTAL
Intervention: Tailored information package including maps of pedestrian injuries for intervention politicians
Number of subjects: 615

Group type: COMPARATOR
Intervention: General information pack for control politicians
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Tailored information package
Number of subjects: 615
Study: 17240625

Group type: EXPERIMENTAL
Intervention: Anagrelide treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with spontaneous platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with ET
Number of subjects: 0
Study: 12784123

Group type: EXPERIMENTAL
Intervention: 7.5 mg THC
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 15 mg THC
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 11111271

Group type: EXPERIMENTAL
Intervention: Needle exchange program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonprogram areas
Number of subjects: 0
Study: 8861742

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice a day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 1462746

Group type: EXPERIMENTAL
Intervention: 5‐FU alone (440 mg/m2 IV bolus 5/21 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Folinic acid (200 mg/m2 IV bolus 5/21 days) preceding 5‐FU (370 mg/m2 in short infusion 5/21 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Immediate post‐operative continuous portal infusion (5‐FU 500 mg/m2/day x 7 followed by a 2 hours infusion of mitomycin C 10 mg/m2)
Number of subjects: 41
Study: 3912956

Group type: EXPERIMENTAL
Intervention: Veadent mouthwash
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 10
Study: 31412688

Group type: EXPERIMENTAL
Intervention: Consumption of vegetables (41.28 g per portion at T0)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Consumption of vegetables (36.67 g per portion at T1)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Consumption of fruit (15.25 g per portion at T1)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (39.26 g per 10 points at T0)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (42.76 g per 10 points at T1)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (10.90 g per portion at T0)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (8.19 g per portion at T1)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Higher sugar consumption at T0 (8.27 g per 10 g)
Number of subjects: 2286

Group type: EXPERIMENTAL
Intervention: Early pregnancy alcohol intake (15.32 g per g)
Number of subjects: 2286
Study: 29373136

Group type: EXPERIMENTAL
Intervention: DyeVert™ system
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (without DyeVert™ system)
Number of subjects: 96
Study: 26509229

Group type: EXPERIMENTAL
Intervention: 1×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 3×15 minutes application of 35% hydrogen peroxide gel
Number of subjects: 53
Study: 24149751

Group type: EXPERIMENTAL
Intervention: Action Observation (AO) group (n = 8) received verbal coaching cues, physical practice, and observed a video of a skilled model before performing each set.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional Coaching (TC) group (n = 7) received standard coaching feedback (verbal cues and physical practice).
Number of subjects: 15
Study: 23061541

Group type: EXPERIMENTAL
Intervention: 3L tubular bandage
Number of subjects: 45

Group type: COMPARATOR
Intervention: Short-stretch compression bandage
Number of subjects: 45
Study: 20935397

Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral doxophylline (400 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 mcg)
Number of subjects: 50
Study: 17660151

Group type: EXPERIMENTAL
Intervention: Culturally adapted WHOQOL‐100 questionnaire
Number of subjects: 1068
Study: 15613417

Group type: EXPERIMENTAL
Intervention: Diet incorporating 30% excess energy as fat
Number of subjects: 14

Group type: COMPARATOR
Intervention: Energy-balanced diet
Number of subjects: 14
Study: 11950108

Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Peer-based intervention
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Combined classroom- and peer-based intervention
Number of subjects: 1532

Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 1532
Study: 10085475

Group type: EXPERIMENTAL
Intervention: 0.6 mg/cm2 melatonin applied 15 min before UV irradiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 20
Study: 8536413

Group type: EXPERIMENTAL
Intervention: Absolute leucocyte differential counts (cells x 10(9)/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proportional leucocyte differential counts (percentage)
Number of subjects: 0
Study: 1703769

Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CisEBP (cisplatin, bleomycin, etoposide, prednisone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Secondary CHOP treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Secondary CisEBP treatment
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CHOP arm
Number of subjects: 85

Group type: COMPARATOR
Intervention: CisEBP arm
Number of subjects: 85
Study: 420756

Group type: EXPERIMENTAL
Intervention: Vitamin B-complex supplementation
Number of subjects: 973

Group type: COMPARATOR
Intervention: Presence of clinical signs of vitamin B-complex deficiency
Number of subjects: 973
Study: 31704508

Group type: EXPERIMENTAL
Intervention: Optic flow consistent with treadmill speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow sinusoidal modulation of the speed (SINE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversals of optic flow velocity (REV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 31474260

Group type: EXPERIMENTAL
Intervention: Fixed palatal crib (FPC) treatment (TG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nontreated (CG)
Number of subjects: 80
Study: 27838097

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Participants with attenuated psychotic symptoms, first-degree relatives, and healthy controls
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia (after accounting for stress)
Number of subjects: 118
Study: 25622825

Group type: EXPERIMENTAL
Intervention: Trout raised on vegetable feeds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trout raised on marine feeds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chicken meal
Number of subjects: 30
Study: 23356210

Group type: EXPERIMENTAL
Intervention: ASKP1240 (0.00003‐10 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21303799

Group type: EXPERIMENTAL
Intervention: Early vaccination (day 4)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Late vaccination (day 16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 20137402

Group type: EXPERIMENTAL
Intervention: Intraprostatic anesthesia plus periprostatic nerve block (PNB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel plus PNB (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intraprostatic anesthesia plus PNB (Group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PNB alone (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No anesthesia (Group A)
Number of subjects: 120
Study: 18196620

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once daily
Number of subjects: 1482

Group type: COMPARATOR
Intervention: atorvastatin 10 mg once daily
Number of subjects: 1482
Study: 15071604

Group type: EXPERIMENTAL
Intervention: alemtuzumab (30 mg i.v. TIW, 12 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: observation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 21
Study: 12143454

Group type: EXPERIMENTAL
Intervention: One leg crossed over the other
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both feet flat on the floor
Number of subjects: 90
Study: 11057002

Group type: EXPERIMENTAL
Intervention: Compatible imagery condition (imagined passive self-motion in the same direction as target acceleration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-compatible imagery condition (imagined passive self-motion in the opposite direction to target acceleration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline condition (without imagery)
Number of subjects: 20
Study: 9073051

Group type: EXPERIMENTAL
Intervention: ChlVPP
Number of subjects: 100

Group type: COMPARATOR
Intervention: ChlVPP/ABOD
Number of subjects: 100
Study: 1671346

Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol (15 mg IV over 6 minutes, followed by 50 mg orally every 12 hours for 24 hours, then 100 mg orally every 12 hours)
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Immediate intravenous metoprolol
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Deferred metoprolol (50 mg orally twice on day 6, then 100 mg orally twice a day thereafter)
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Deferred metoprolol
Number of subjects: 1434
Study: 6883915

Group type: EXPERIMENTAL
Intervention: Zomepirac (400 mg and 800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (15 mg and 30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30285092

Group type: EXPERIMENTAL
Intervention: Strength endurance training (40% one-repetition maximum)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intensive strength training (80% of one-repetition maximum)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (stretching exercise)
Number of subjects: 100
Study: 30292000

Group type: EXPERIMENTAL
Intervention: Staple line inversion (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Staple line reinforcement with buttressing material (Group 2)
Number of subjects: 100
Study: 26314234

Group type: EXPERIMENTAL
Intervention: Intradiskal PRP
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (contrast agent)
Number of subjects: 47
Study: 23850254

Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Radical nephrectomy (RN)
Number of subjects: 541
Study: 22459201

Group type: EXPERIMENTAL
Intervention: 100mg of MDMA
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d‐methamphetamine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 20458441

Group type: EXPERIMENTAL
Intervention: Enoxaparin 80 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 49
Study: 17122975

Group type: EXPERIMENTAL
Intervention: Combination of virtual reality training and inanimate box training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Virtual reality training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Inanimate box training
Number of subjects: 65

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 65
Study: 16115831

Group type: EXPERIMENTAL
Intervention: Two intramuscular doses of 12 mg betamethasone in the 48 hours before delivery
Number of subjects: 998

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 998
Study: 11842389

Group type: EXPERIMENTAL
Intervention: FND (fludarabine/mitoxantrone/dexamethasone) plus rituximab
Number of subjects: 152
Study: 10401895

Group type: EXPERIMENTAL
Intervention: Consumer team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-consumer team
Number of subjects: 0
Study: 8640466

Group type: EXPERIMENTAL
Intervention: Early oral hydration (sips of fruit juices sweetened with honey, solid food 24 hours later)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional intravenous hydration (2-3 L of dextrose saline/24 hours, solid food thereafter)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early oral hydration
Number of subjects: 200